dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials

BACKGROUND AND OBJECTIVE Dose-finding, aiming at finding the maximum tolerated dose, and pharmacokinetics studies are the first in human studies in the development process of a new pharmacological treatment. In the literature, to date only few attempts have been made to combine pharmacokinetics and dose-finding and to our knowledge no software implementation is generally available. In previous papers, we proposed several Bayesian adaptive pharmacokinetics-based dose-finding designs in small populations. The objective of this work is to implement these dose-finding methods in an R package, called dfpk. METHODS All methods were developed in a sequential Bayesian setting and Bayesian parameter estimation is carried out using the rstan package. All available pharmacokinetics and toxicity data are used to suggest the dose of the next cohort with a constraint regarding the probability of toxicity. Stopping rules are also considered for each method. The ggplot2 package is used to create summary plots of toxicities or concentration curves. RESULTS For all implemented methods, dfpk provides a function (nextDose) to estimate the probability of efficacy and to suggest the dose to give to the next cohort, and a function to run trial simulations to design a trial (nsim). The sim.data function generates at each dose the toxicity value related to a pharmacokinetic measure of exposure, the AUC, with an underlying pharmacokinetic one compartmental model with linear absorption. It is included as an example since similar data-frames can be generated directly by the user and passed to nsim. CONCLUSION The developed user-friendly R package dfpk, available on the CRAN repository, supports the design of innovative dose-finding studies using PK information.

[1]  F Bretz,et al.  Combining Multiple Comparisons and Modeling Techniques in Dose‐Response Studies , 2005, Biometrics.

[2]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[3]  J Whitehead,et al.  A novel Bayesian decision procedure for early-phase dose-finding studies. , 1999, Journal of biopharmaceutical statistics.

[4]  Sarah Zohar,et al.  A Survey of the Way Pharmacokinetics are Reported in Published Phase I Clinical Trials, with an Emphasis on Oncology , 2009, Clinical pharmacokinetics.

[5]  Hartmut Derendorf,et al.  Pharmacokinetic/Pharmacodynamic Modeling in Drug Research and Development , 2000, Journal of clinical pharmacology.

[6]  S. Piantadosi,et al.  Improved designs for dose escalation studies using pharmacokinetic measurements. , 1996, Statistics in medicine.

[7]  France Mentré,et al.  Influence of the Size of Cohorts in Adaptive Design for Nonlinear Mixed Effects Models: An Evaluation by Simulation for a Pharmacokinetic and Pharmacodynamic Model for a Biomarker in Oncology , 2015, Pharmaceutical Research.

[8]  Moreno Ursino,et al.  Dose‐finding methods for Phase I clinical trials using pharmacokinetics in small populations , 2017, Biometrical journal. Biometrische Zeitschrift.

[9]  J Whitehead,et al.  Easy-to-implement Bayesian methods for dose-escalation studies in healthy volunteers. , 2001, Biostatistics.

[10]  J O'Quigley,et al.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.

[11]  John Whitehead,et al.  A Bayesian Approach for Dose-Escalation in a Phase I Clinical Trial Incorporating Pharmacodynamic Endpoints , 2007, Journal of biopharmaceutical statistics.